Stirling study exposes failing workplace cancer compensation scheme

Professor Andrew Watterson
Professor Andrew Watterson
1 April 2015

Workers suffering occupational cancer and other potentially lethal work-related diseases can forget about any Government compensation, according to a new report by University of Stirling health researchers.

The Stirling report finds the current compensation scheme excludes seven of the top ten entries on the official UK occupational cancer priorities ranking.

Diesel exhaust or painting-related lung or bladder cancer are not on the prescribed disease list, nor is welding-related lung cancer. Skin cancer caused by solar radiation exposure, a known problem in outdoor workers and pilots, is also missing.

Women almost entirely miss out, with breast cancer caused by shiftwork - estimated by the Health & Safety Executive (HSE) to affect around 2000 women each year - omitted from the list of 'prescribed' industrial diseases for which state compensation Industrial Injuries Disablement Benefit (IIDB) is payable.

Also missing is asbestos-related ovarian cancer, the most common gynaecological cancer in British women, despite having the top International Agency for Research on Cancer (IARC) cancer risk rating.

Professor Andrew Watterson, Head of the University’s Occupational and Environmental Health Research Group, said: “The UK Government’s workplace compensation scheme requires urgent reform. It is an unholy mess with only a tiny proportion of those made sick by their work in with a sniff of any compensation.

“The Industrial Injuries Disablement Benefit (IIDB) scheme excludes many conditions and those that are covered tend to be subject to claim-barring disability thresholds, minimum exposure times and job restrictions.”

HSE data conservatively indicates almost 13,600 new cases of occupational cancer each year, yet in 2012, IIDB compensated just 2,600 cases. Remove asbestos-related cancers and just 90 payouts were made, a 1% chance of compensation.

The report is strongly critical of the role played by the Industrial Injuries Advisory Council (IIAC), which recommends which conditions should be added to the prescribed disease list.

Report co-author, Professor Rory O'Neill said: “The IIAC approach hovers between incompetent and wrong. It imposes an arbitrary 'relative risk' prescription test, requiring the condition to be twice as common in the affected group than in the general population. Even uncontentious causes of occupational cancer won't surmount this.

“The government prescribed disease scheme might just be capable of spotting a catastrophe but does nothing to recognise, compensate or avert tens of thousands of personal, preventable and frequently fatal human tragedies.”

The full report is published in Hazards, an online magazine providing guidance and advice for workplace unions.

Health research at Stirling is ranked No.1 in Scotland and in the top 25% in its field across the UK in the 2014 Research Excellence Framework.

Their findings follow a 2012 Stirling study of more than 2000 women in Canada which found a 42% increased risk of breast cancer for those exposed at work to high levels of certain chemicals.

David Christie
Communications Officer
01786 466653
david.christie1@stir.ac.uk

Background information

 

Industrial Injuries Advisory Council (IIAC) Cancer Omissions

The table below outlines the top 10 cancer prevention priority rankings by the Health & Safety Executive in 2012 and whether the related cancer is a prescribed disease recognised by the Department of Work and Pensions (DWP) Industrial Injuries Disablement Benefit (IIDB).

HSE 2012 Cancer priority ranking and IIDB Prescribed disease

  1. Asbestos: Mesothelioma [yes]; lung [yes]; larynx [no]; stomach [no]
  2. Silica: Lung [yes]
  3. Shiftwork: Breast [no]
  4. Welding: Lung [no]
  5. Painting: Lung [no]; bladder [no]
  6. Diesel exhaust emissions: Lung [no]; bladder [no]
  7. Solar radiation: Non melanoma skin cancer [no]
  8. PAHs – coal tar and pitches: Non melanoma skin cancer [no]
  9. Tetrachloroethylene: Cervix [no]; Non-Hodgkin’s lymphoma [no]; oesophagus [no]
  10. Radon: Lung [no]

 

The University of Stirling is ranked fifth in Scotland and 40th in the UK for research intensity in the 2014 Research Excellence Framework. Stirling is committed to carrying out research which has a positive impact on communities across the globe – addressing real issues, providing solutions and helping to shape society. Interdisciplinary in its approach, Stirling’s research informs its teaching curriculum and facilitates opportunities for knowledge exchange and collaboration between staff, students, industry partners and the wider community. At almost 50-years-young, Stirling retains a pioneering spirit and a passion for innovation. Its scenic central Scotland campus – complete with a loch, castle and golf course – is home to more than 11,000 students and 1400 staff representing 115 nationalities. This includes an ever-expanding base for postgraduate study.
www.stir.ac.uk

© University of Stirling FK9 4LA Scotland UK • Telephone +44 1786 473171 • Scottish Charity No SC011159
Portal Logon

Forgotten login?

×